Overview

Prospective Evaluation of the QoL of Patients With PTS Who Receive Compression Therapy and Sulodexide

Status:
Terminated
Trial end date:
2017-02-01
Target enrollment:
Participant gender:
Summary
This study aims to evaluate whether, in a standardised cohort of patients with mild to moderate PTS, monitored for a sufficiently long follow-up period, quality of life measured by generic instruments and disease-specific instruments evolves favourably in this patient profile. Study objective: to evaluate the evolution of quality of life in general and in the specific context of the disease of patients who have experienced an episode of deep-vein thrombosis (DVT), are affected by post-thrombotic syndrome, are subject to compression therapy and receive an additional standard venoactive agent (sulodexide 15 mg twice daily during 6 months).
Phase:
Phase 4
Details
Lead Sponsor:
Bama GeVe, S.L.U.
Treatments:
Glucuronyl glucosamine glycan sulfate